For instance, Montero-Conde et al. demonstrated that the BRAF inhibitor promotes the expression and activation of human epidermal growth factor receptor (HER)2/HER3 heterodimers depending on autocrine neuregulin-1 (NRG-1) binding to HER3 in thyroid cancers harboring BRAF mutation [62]. This evidence concerns the gene NRG1 and thyroid gland carcinoma.